“South Africa’s selective rollout of lenacapavir, a promising HIV prevention jab, has sparked debate about unequal access. Communities in Gauteng report readiness gaps, leaving vulnerable populations unprotected.”
The introduction of lenacapavir was hailed as a breakthrough in HIV prevention. However, the rollout has been geographically selective, with clinics in Gauteng showing uneven readiness. Patients report confusion, long queues, and inconsistent availability. Public health experts warn that this selective distribution risks widening inequalities, as rural and marginalized communities remain excluded. Civil society organizations argue that prevention should be universal, not selective, and call for transparent allocation strategies. The Department of Health insists that logistical constraints necessitate phased implementation, but activists counter that this approach undermines trust. The debate underscores South Africa’s ongoing struggle to balance innovation with equitable access in its fight against HIV.
